FDA approves Oyster Point's nasal spray for dry eye disease | Inquirer News
Close  

FDA approves Oyster Point’s nasal spray for dry eye disease

/ 06:58 PM October 18, 2021
FILE PHOTO: Signage is seen outside of FDA headquarters in White Oak, Maryland

FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

Drug developer Oyster Point Pharma Inc said on Monday the U.S. Food and Drug Administration had approved its nasal spray treatment for dry eye disease.

The company said the spray, Tyrvaya, will be available from next month to patients with a prescription.

ADVERTISEMENT

The regulator’s decision was based on safety and efficacy results from a late-stage and two mid-stage trials covering over 1,000 patients with mild, moderate or severe symptoms of dry eye disease (DED).

More than 30 million people in the United States are affected by the chronic condition characterized by stinging, sensitivity to light, blurred vision and eye fatigue.

FEATURED STORIES

Oyster Point in March said data from the trials showed that Tyrvaya demonstrated statistically significant improvement in production of tear film on eye surface in all trials.

Tear film helps to keep eyes moist, reducing risks of infection and contributing to clear vision.

“A product that provides clinically meaningful production of basal tear film as early as four weeks is incredible for the dry eye patient,” Ed Holland, director of cornea services at Cincinnati Eye Institute and professor of ophthalmology at University of Cincinnati said in the company’s statement.

Tyrvaya is a nasal spray formulation of the drug varenicline, also used in Pfizer Inc’s smoking cessation drug, Chantix.

Tyrvaya works by activating a nerve that stimulates natural tear film production, and in turn relieving symptoms of dry eye disease.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.
Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: dry eye disease (DED), nasal spray, Oyster Point, Tyrvaya, US Food and Drug Administration
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.